Praxis Awarded Patient Recruitment Contract For International Type 2 Diabetes Study

Praxis Awarded Patient Recruitment Contract For International Type 2 Diabetes Study 
BRENTWOOD, Tenn. - (Business Wire) Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a top 20 pharmaceutical company for an international study on type 2 diabetes. The study explores an investigational drug's effectiveness for maintaining glycemic control for individuals newly diagnosed with type 2 diabetes.

There are currently an estimated 171 million individuals worldwide with a diagnosis of type 2 diabetes and that number is expected to grow. These statistics only highlight the need for new compounds and forms of treatment for type 2 diabetes and explains why metabolic disorders fall within the top 5 therapeutic areas currently of being studied.

"Praxis' historical successes in recruiting for type 2 diabetes made the opportunity to be a part of this study even more exciting," said Praxis President and CEO, David Fox. "With so many competing treatment options for individuals with type 2 diabetes, a well thought out and strategic recruitment effort was clearly needed to ensure a timely enrollment. We look forward to seeing this trial through to success."

A full complement of marketing and communications tools will be implemented in the U.S. and five other participating countries, based on strategic predictive modeling data from PraxisDirect, Praxis' real-time study management software.

Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit


Praxis Communications, Inc.
Chris Layfield
Director of Marketing

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.